191 related articles for article (PubMed ID: 2106740)
1. First and second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection followed by testing for anti-OKT3 IgM and/or IgG immunization.
Birkeland SA; Bach JF; Chatenoud L; Jørgensen KA; Strate M; Elbirk A; Rohr N; Svendsen V
Transplant Proc; 1990 Feb; 22(1):221-2. PubMed ID: 2106740
[No Abstract] [Full Text] [Related]
2. Treatment of acute rejection with anti-T-cell antigen receptor complex alpha beta (T10B9.1A-31) or anti-CD3 (OKT3) monoclonal antibody: results of a prospective randomized double-blind trial.
Waid TH; Lucas BA; Thompson JS; Munch LC; Brown S; Kryscio R; Prebeck R; VanHoy MA; Jezek D
Transplant Proc; 1991 Feb; 23(1 Pt 2):1062-5. PubMed ID: 1899152
[No Abstract] [Full Text] [Related]
3. Orthoclone OKT3 as first-line therapy in acute renal allograft rejection.
Strate M; Jørgensen KA; Rohr N; Elbirk A; Svendsen V; Birkeland SA
Transplant Proc; 1990 Feb; 22(1):219-20. PubMed ID: 2106739
[No Abstract] [Full Text] [Related]
4. Treatment with OKT3 and cyclosporine for acute allograft rejection.
Schulak JA; Mayes JT; Hricik DE
Transplant Proc; 1991 Aug; 23(4):2119-22. PubMed ID: 1908150
[TBL] [Abstract][Full Text] [Related]
5. Isolation of anti-OKT3 and anti-(anti-OKT3) from a kidney transplant recipient.
Fuller L; Carreno M; Zheng S; Esquenazi V; Yang W; Miller J
Transplant Proc; 1991 Feb; 23(1 Pt 1):305-6. PubMed ID: 1899306
[No Abstract] [Full Text] [Related]
6. Immunologic monitoring with Orthoclone OKT3 therapy.
Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
[TBL] [Abstract][Full Text] [Related]
7. Acute renal allograft rejection: the role of monoclonal antibodies in treatment: experience with orthoclonal anti-T3 cell antibody.
McLigeyo SO; Notghi A; Anderton JL; Dick J
East Afr Med J; 1990 Sep; 67(9):667-73. PubMed ID: 2123786
[TBL] [Abstract][Full Text] [Related]
8. Orthoclone OKT3 as rescue treatment for steroid-resistant and recurrent acute rejection in clinical renal transplantation.
Tvedegaard E; Olgaard K
Transplant Proc; 1990 Feb; 22(1):217-8. PubMed ID: 2106738
[No Abstract] [Full Text] [Related]
9. Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation.
Goldstein G
Transplant Proc; 1987 Apr; 19(2 Suppl 1):1-6. PubMed ID: 3105134
[No Abstract] [Full Text] [Related]
10. Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines.
Abbs IC; Clark M; Waldmann H; Chatenoud L; Koffman CG; Sacks SH
Ther Immunol; 1994 Dec; 1(6):325-31. PubMed ID: 7584508
[TBL] [Abstract][Full Text] [Related]
11. Immunological follow-up of renal allograft recipients treated with the BMA 031 (anti-TCR) monoclonal antibody.
Chatenoud L; Ferran C; Legendre C; Kurrle R; Kreis H; Bach JF
Transplant Proc; 1990 Aug; 22(4):1787-8. PubMed ID: 2117809
[No Abstract] [Full Text] [Related]
12. Anaphylaxis and desensitization to the murine monoclonal antibody used for renal graft rejection.
Georgitis JW; Browning MC; Steiner D; Lorentz WB
Ann Allergy; 1991 Apr; 66(4):343-7. PubMed ID: 1901692
[TBL] [Abstract][Full Text] [Related]
13. The reuse of OKT3 after previous rejection or induction therapy in cadaveric renal transplantation.
Shield CF; Hughes JD
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):35-8. PubMed ID: 2510509
[TBL] [Abstract][Full Text] [Related]
14. The treatment of steroid-resistant renal allograft rejection with OKT3 and plasmapheresis.
Haberal M; Sert S; Gülay H; Arslan G; Bilgin N
Transplant Proc; 1990 Aug; 22(4):1761-3. PubMed ID: 2117801
[No Abstract] [Full Text] [Related]
15. Immunologic monitoring in OKT3-treated kidney graft recipients.
Zlabinger GJ; Maurer D; Ulrich W; Meron G; Pohanka E; Kovarik J
Transplant Proc; 1990 Aug; 22(4):1777-8. PubMed ID: 2117807
[No Abstract] [Full Text] [Related]
16. Use of Orthoclone OKT3 monoclonal antibody to reverse acute renal allograft rejection unresponsive to treatment with conventional immunosuppressive regimens.
Monaco A; Goldstein G; Barnes L
Transplant Proc; 1987 Apr; 19(2 Suppl 1):28-31. PubMed ID: 3105137
[No Abstract] [Full Text] [Related]
17. T10B9.1A-31 anti-T-cell monoclonal antibody: preclinical studies and clinical treatment of solid organ allograft rejection.
Waid TH; Lucas BA; Amlot P; Janossy G; Yacoub M; Cammisuli S; Jezek D; Rhoades J; Brown S; Thompson JS
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):61-70. PubMed ID: 2479265
[TBL] [Abstract][Full Text] [Related]
18. Fibrinoid necrosis of a temporal artery complicating the treatment of refractory cardiac allograft rejection with murine monoclonal CD3 antibody (OKT3).
Hammond EH; Watson FS; Bristow MR; O'Connell JB; Gilbert EM; Doty DB; Renlund DG
J Heart Transplant; 1990; 9(3 Pt 1):236-8. PubMed ID: 2113090
[TBL] [Abstract][Full Text] [Related]
19. OKT3 for induction immunosuppression in renal transplantation: a comparative study of high versus low doses.
Norman DJ; Barry JM; Bennett WM; Munson JL; Meyer M; Henell K; Kimball J; Hubert B
Transplant Proc; 1991 Feb; 23(1 Pt 2):1052-4. PubMed ID: 1846453
[No Abstract] [Full Text] [Related]
20. T10B9 (MEDI-500) mediated immunosuppression: studies on the mechanism of action.
Brown SA; Lucas BA; Waid TH; McKeown JW; Barve S; Jackson LR; Thompson JS
Clin Transplant; 1996 Dec; 10(6 Pt 2):607-13. PubMed ID: 8996751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
